Bayer AG (BAYRY) Receives Average Rating of “Hold” from Analysts
Shares of Bayer AG (OTCMKTS:BAYRY) have earned a consensus rating of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company.
BAYRY has been the topic of a number of recent analyst reports. ValuEngine raised Bayer from a “strong sell” rating to a “sell” rating in a research report on Monday, February 4th. JPMorgan Chase & Co. downgraded Bayer from an “overweight” rating to a “neutral” rating in a research report on Wednesday, January 2nd. Finally, Zacks Investment Research downgraded Bayer from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 23rd.
BAYRY stock traded down $0.05 during midday trading on Wednesday, hitting $18.80. 107,981 shares of the company’s stock were exchanged, compared to its average volume of 514,399. The firm has a market cap of $70.05 billion, a PE ratio of 9.89, a P/E/G ratio of 1.28 and a beta of 0.96. Bayer has a one year low of $16.58 and a one year high of $32.80. The company has a current ratio of 1.59, a quick ratio of 1.04 and a debt-to-equity ratio of 0.80.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: What impact do institutional investors have on markets?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.